Dobrindt Kristina, Zhang Hanwen, Das Debamitra, Abdollahi Sara, Prorok Tim, Ghosh Sulagna, Weintraub Sarah, Genovese Giulio, Powell Samuel K, Lund Anina, Akbarian Schahram, Eggan Kevin, McCarroll Steven, Duan Jubao, Avramopoulos Dimitrios, Brennand Kristen J
Pamela Sklar Division of Psychiatric Genomics, Department of Genetics and Genomics, Icahn Institute of Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Nash Family Department of Neuroscience, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Complex Psychiatry. 2021 Feb;6(3-4):68-82. doi: 10.1159/000512716. Epub 2020 Nov 2.
Schizophrenia (SZ) is a common and debilitating psychiatric disorder with limited effective treatment options. Although highly heritable, risk for this polygenic disorder depends on the complex interplay of hundreds of common and rare variants. Translating the growing list of genetic loci significantly associated with disease into medically actionable information remains an important challenge. Thus, establishing platforms with which to validate the impact of risk variants in cell-type-specific and donor-dependent contexts is critical. Towards this, we selected and characterized a collection of 12 human induced pluripotent stem cell (hiPSC) lines derived from control donors with extremely low and high SZ polygenic risk scores (PRS). These hiPSC lines are publicly available at the California Institute for Regenerative Medicine (CIRM). The suitability of these extreme PRS hiPSCs for CRISPR-based isogenic comparisons of neurons and glia was evaluated across 3 independent laboratories, identifying 9 out of 12 meeting our criteria. We report a standardized resource of publicly available hiPSCs on which we hope to perform genome engineering and generate diverse kinds of functional data, with comparisons across studies facilitated by the use of a common set of genetic backgrounds.
精神分裂症(SZ)是一种常见且使人衰弱的精神疾病,有效的治疗选择有限。尽管具有高度遗传性,但这种多基因疾病的风险取决于数百种常见和罕见变异的复杂相互作用。将越来越多与疾病显著相关的基因座转化为医学上可操作的信息仍然是一项重大挑战。因此,建立能够在细胞类型特异性和供体依赖性背景下验证风险变异影响的平台至关重要。为此,我们选择并鉴定了一组12个人诱导多能干细胞(hiPSC)系,这些细胞系来自具有极低和极高SZ多基因风险评分(PRS)的对照供体。这些hiPSC系可在加利福尼亚再生医学研究所(CIRM)公开获取。在3个独立实验室中评估了这些极端PRS hiPSC用于基于CRISPR的神经元和神经胶质细胞等基因比较的适用性,确定12个中有9个符合我们的标准。我们报告了一种公开可用的hiPSC标准化资源,我们希望在其上进行基因组工程并生成各种功能数据,通过使用一组共同的遗传背景促进跨研究比较。